Literature DB >> 31188186

Does Metabolic Syndrome Increase the Risk of Postoperative Complications in Patients Undergoing Colorectal Cancer Surgery?

Omair A Shariq1, Kristine T Hanson2, Nicholas P McKenna1, Scott R Kelley1, Eric J Dozois1, Amy L Lightner1, Kellie L Mathis1, Elizabeth B Habermann2.   

Abstract

BACKGROUND: Metabolic syndrome is associated with poorer postoperative outcomes after various abdominal operations. However, the impact of metabolic syndrome on outcomes after colorectal cancer surgery remains poorly described.
OBJECTIVE: The purpose of this study was to determine the association between metabolic syndrome and short-term postoperative outcomes in patients undergoing elective colorectal cancer surgery.
DESIGN: This was a retrospective cohort study. SETTINGS: This study used a national multicenter database. PATIENTS: Adult patients who underwent elective colectomy for colorectal cancer from 2010 to 2016 were identified in the American College of Surgeons National Surgical Quality Improvement Program database. MAIN OUTCOME MEASURES: Thirty-day postoperative mortality and morbidity, unplanned reoperation, unplanned readmission, operative time, and length of stay were measured.
RESULTS: A total of 91,566 patients were analyzed; 7603 (8.3%) had metabolic syndrome. On unadjusted analysis, metabolic syndrome was associated with an increased risk of 30-day overall morbidity, pulmonary complications, renal complications, septic complications, cardiac complications, wound complications, blood transfusion, longer length of stay, and unplanned readmissions. On multivariable analysis, metabolic syndrome remained significantly associated with renal complications (OR = 1.44 (95% CI, 1.29-1.60)), superficial surgical site infection (OR = 1.46 (95% CI, 1.32-1.60)), deep surgical site infection (OR = 1.40 (95% CI, 1.15-1.70)), wound dehiscence (OR = 1.47 (95% CI, 1.20-1.80)), and unplanned readmissions (HR = 1.24 (95% CI, 1.15-1.34)). The risks of overall morbidity, cardiac and septic complications, and prolonged length of stay for laparoscopic procedures were significantly associated with diabetes mellitus rather than metabolic syndrome as a composite entity. LIMITATIONS: This study was limited by its retrospective design and inability to analyze outcomes beyond 30 days.
CONCLUSIONS: Patients with metabolic syndrome undergoing elective surgery for colorectal cancer have an increased risk of 30-day postoperative renal complications, wound complications, and unplanned hospital readmissions. A multidisciplinary approach involving lifestyle modifications and pharmacologic interventions to improve the components of metabolic syndrome should be implemented preoperatively for these patients. See Video Abstract at http://links.lww.com/DCR/A909.

Entities:  

Mesh:

Year:  2019        PMID: 31188186     DOI: 10.1097/DCR.0000000000001334

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  10 in total

1.  Impact of Metabolic Syndrome on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Hepatectomy.

Authors:  Alessandro Paro; Diamantis I Tsilimigras; Djhenne Dalmacy; Rayyan S Mirdad; J Madison Hyer; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2021-02-05       Impact factor: 3.452

2.  Modified Metabolic Syndrome Predicts Worse Outcomes in Obese Patients Undergoing Inguinal Hernia Repair.

Authors:  Adrienne B Shannon; Rachel R Kelz; Noel N Williams; Giorgos C Karakousis; Kristoffel R Dumon
Journal:  J Gastrointest Surg       Date:  2020-11-18       Impact factor: 3.452

3.  Pancreatoduodenectomy: the Metabolic Syndrome is Associated with Preventable Morbidity and Mortality.

Authors:  Victor P Gazivoda; Alissa Greenbaum; Matthew A Beier; Catherine H Davis; Aaron W Kangas-Dick; Russell C Langan; Miral S Grandhi; David A August; H Richard Alexander; Henry A Pitt; Timothy J Kennedy
Journal:  J Gastrointest Surg       Date:  2022-06-29       Impact factor: 3.267

4.  The Association Between Metabolic Derangement and Wound Complications in Elective Plastic Surgery.

Authors:  Amanda R Sergesketter; Yisong Geng; Ronnie L Shammas; Gerald V Denis; Robin Bachelder; Scott T Hollenbeck
Journal:  J Surg Res       Date:  2022-05-16       Impact factor: 2.417

5.  Defining Microbiome Readiness for Surgery: Dietary Prehabilitation and Stool Biomarkers as Predictive Tools to Improve Outcome.

Authors:  Robert Keskey; Emily Papazian; Adam Lam; Tiffany Toni; Sanjiv Hyoju; Renee Thewissen; Alexander Zaborin; Olga Zaborina; John C Alverdy
Journal:  Ann Surg       Date:  2020-11-04       Impact factor: 13.787

6.  A new sarcopenia score prognostic for postoperative complications in hepatic alveolar echinococcosis: a multicenter retrospective study.

Authors:  Tao Wang; Xianwei Yang; Wanxiang Wang; Tingyu Chen; Junjie Kong; Shu Shen; Ying Chen; Gengfu Wei; Dinggang Yu; Cong Wang; Minghao Li; Shaozhen Rui; Biao Luo; Wentao Wang
Journal:  Ann Transl Med       Date:  2020-11

Review 7.  Metabolic syndrome; associations with adverse outcome after colorectal surgery. A systematic review and meta-analysis.

Authors:  M Reudink; C D Slooter; L Janssen; A G Lieverse; R M H Roumen; G D Slooter
Journal:  Ann Med Surg (Lond)       Date:  2021-11-03

8.  Predictive factors of early outcome after palliative surgery for colorectal carcinoma.

Authors:  Ralf Konopke; Jörg Schubert; Oliver Stöltzing; Tina Thomas; Stephan Kersting; Axel Denz
Journal:  Innov Surg Sci       Date:  2020-11-02

9.  The Impact of Comorbid Diabetes on Short-Term Postoperative Outcomes in Stage I/II Colon Cancer Patients Undergoing Open Colectomy.

Authors:  Ko-Chao Lee; Kuan-Chih Chung; Hong-Hwa Chen; Kung-Chuan Cheng; Kuen-Lin Wu; Ling-Chiao Song; Wan-Hsiang Hu
Journal:  Biomed Res Int       Date:  2020-08-04       Impact factor: 3.411

10.  Is metabolic syndrome a risk factor in hepatectomy? A meta-analysis with subgroup analysis for histologically confirmed hepatic manifestations.

Authors:  Anastasia Murtha-Lemekhova; Juri Fuchs; Svenja Feiler; Erik Schulz; Miriam Teroerde; Eva Kalkum; Rosa Klotz; Adrian Billeter; Pascal Probst; Katrin Hoffmann
Journal:  BMC Med       Date:  2022-01-28       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.